Lumida
/CLDX
⌘K
Celldex Therapeutics Inc

Celldex Therapeutics Inc

CLDX
$36.90USD-3.15%-1.20 today

MARKET CAP

2.9B

P/E (TTM)

FWD P/E

DAY RANGE

$37 – $39

52W RANGE

$22
$45

AI Summary

Stalk
Sell NowMedium

CLDX has broken decisively below its key support around 38.8–39.4 in a Stage 3 distribution context, confirming supply dominance. Short-term price is extended below declining EMAs with no exhaustion visible, justifying Sell Now into the broken support–turned–resistance zone for continuation participation.

  • Phase 1 CDX-622 delivered dose-dependent, durable serum tryptase reductions.
  • Two Phase 3 barzolvolimab trial readouts in late 2026 could spark stock gains.
  • Profitability remains deeply negative, highlighting ongoing net losses.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$4.7M$2.4M$6.9M$7.0M$1.5M
YoY %-37.3%-49.3%+192.0%+2.0%-78.0%
P / Sales356.2x863.2x284.4x231.8x1167.7x
EV / Sales353.2x861.9x284.7x234.2x1185.1x
Gross Profit, Adj.$4.7M$2.4M$6.9M$7.0M$1.5M
YoY %-37.3%-49.3%+192.0%+2.0%-78.0%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit353.2x861.9x284.7x234.2x1185.1x
EBITDA, Adj.$-66.1M$-104.2M$-139.0M$-191.9M$-284.0M
YoY %-44.8%-57.7%-33.4%-38.0%-48.0%
Margin %-1420.8%-4420.9%-2020.0%-2733.6%-18381.0%
EV / EBITDA-24.9x-19.5x-14.1x-8.6x-6.4x
EBIT$-72.6M$-115.2M$-154.5M$-195.1M$-287.4M
YoY %-7.5%-58.6%-34.1%-26.2%-47.3%
Margin %-1562.0%-4889.0%-2245.3%-2778.9%-18599.8%
EV / EBIT-22.6x-17.6x-12.7x-8.4x-6.4x
Net Income$-70.5M$-112.3M$-141.4M$-157.9M$-258.8M
YoY %-18.0%-59.3%-25.9%-11.6%-63.9%
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-16748.0%
EPS (GAAP)-$1.64-$2.40-$2.92-$2.45-$3.90
YoY %+18.8%-46.3%-21.7%+16.1%-59.2%